USANA Health Sciences (NYSE:USNA – Get Free Report) issued an update on its FY 2025 earnings guidance on Tuesday morning. The company provided EPS guidance of 2.350-3.000 for the period, compared to the consensus EPS estimate of 2.870. The company issued revenue guidance of $920.0 million-$1.0 billion, compared to the consensus revenue estimate of $934.5 million.
Wall Street Analyst Weigh In
A number of research firms have recently issued reports on USNA. DA Davidson boosted their price objective on USANA Health Sciences from $35.00 to $38.00 and gave the company a “neutral” rating in a research report on Thursday, January 2nd. Sidoti downgraded shares of USANA Health Sciences from a “strong-buy” rating to a “hold” rating in a research note on Tuesday, February 18th. Finally, StockNews.com cut shares of USANA Health Sciences from a “strong-buy” rating to a “buy” rating in a research note on Friday, February 14th.
Get Our Latest Stock Report on USANA Health Sciences
USANA Health Sciences Stock Down 2.4 %
USANA Health Sciences (NYSE:USNA – Get Free Report) last released its earnings results on Tuesday, February 25th. The company reported $0.64 earnings per share for the quarter, topping analysts’ consensus estimates of $0.49 by $0.15. USANA Health Sciences had a return on equity of 10.64% and a net margin of 6.30%. Equities analysts expect that USANA Health Sciences will post 2.45 EPS for the current year.
USANA Health Sciences Company Profile
USANA Health Sciences, Inc develops, manufactures, and sells science-based nutritional, personal care, and skincare products in the Asia Pacific, the Americas, and Europe. The company offers USANA nutritional products that comprise essentials/CellSentials, such as vitamin and mineral supplements that provide a foundation of total body nutrition for various age groups; optimizers consisting of targeted supplements that are designed to meet cardiovascular, skeletal/structural, and digestive health needs; and food that include meal replacement shakes, snack bars, and other related products.
Further Reading
- Five stocks we like better than USANA Health Sciences
- Breakout Stocks: What They Are and How to Identify Them
- Nebius Slides Post-Earnings: A Long-Term Buy Opportunity?
- Insider Selling Explained: Can it Inform Your Investing Choices?
- NVIDIA Stock: A Market Barometer in Tech’s Turbulent Times
- The Role Economic Reports Play in a Successful Investment Strategy
- Palantir Stock Nears Bear Market Territory – Why and What’s Next?
Receive News & Ratings for USANA Health Sciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for USANA Health Sciences and related companies with MarketBeat.com's FREE daily email newsletter.